Trial Profile
Safety and efficacy of novel oral anticoagulants (warfarin, dabigatran and rivaroxaban) in patients with nonvalvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Apr 2018
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2018 New trial record